The non-invasive transcranial magnetic stimulation device will be used to treat cognitive damage from major depression, bipolar depression, and schizophrenia.
Brainsway Ltd. (TASE:BRIN) has obtained Israel's Ministry of Health approval to market is Deep TMS (transcranial magnetic stimulation) device for the non-invasive treatment of patients with cognitive damage from major depression, bipolar depression, and schizophrenia. The approval applies to four medical centers.
Brainsway CEO Uzi Soffer, said, "This approval is a vote of confidence in the Deep TMS technology in Israel, following its approval in Europe. We are currently working to update indications with the Israeli Ministry of Health in line with the approvals we've received in Europe."
Brainsway's share price rose 1.1% by midday to NIS 17.14, giving a market cap of NIS 200 million.
Published by Globes [online], Israel business news - www.globes-online.com - on October 2, 2011
© Copyright of Globes Publisher Itonut (1983) Ltd. 2011